Mandate

Vinge advises Cinclus Pharma in connection with listing on Nasdaq Stockholm

Vinge advises Cinclus Pharma Holding AB (publ) (“Cinclus Pharma”) in connection with an offering of new ordinary shares and listing on Nasdaq Stockholm. The first day of trading is 20 June 2024.

The offering will provide Cinclus Pharma with proceeds of approximately SEK 787 million before deduction of issue costs and provided that the over-allotment option is fully exercised. In connection with the offering, Cinclus Pharma also carries out a set-off issue at the offering price to convert outstanding bridge loans. 

Cinclus Pharma is a clinical-stage pharmaceutical company focused on the development of the drug candidate linaprazan glurate, a proprietary “prodrug” of the molecule linaprazan. Linaprazan glurate represents a new and innovative mode of action for the treatment of erosive GERD.

Vinge's team mainly consists of Dain Hård Nevonen,Amanda Knutsson, Anna Svensson,Michaela Ådén and Filip Magnusson (Capital Markets and Public M&A), Stojan Arnestål (IP/Life science), Maria Schultzberg (Corporate taxation), Mathilda Persson (Commercial agreements), Gulestan Ali (Compliance), Nicklas Thorgerzon (IT/GDPR), Jonatan Stentorp (Employment) and Sofia Haggren (Financing).

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025